Perry van Doormaal completed his medical training and neurology residency at the UMC Utrecht. During this residency, he obtained his PhD with a thesis on genetic and exposome-related risk factors in amyotrophic lateral sclerosis (ALS).

He subsequently pursued a postdoctoral fellowship at the Johns Hopkins School of Medicine, where he specialized in big data and multi-omics analyses in chronic idiopathic axonal polyneuropathy (CIAP). He then received a neuromuscular fellowship funded by the Prinses Beatrix Spierfonds, conducted jointly at Maastricht UMC+ and UMC Utrecht.

His current research at the UMC Utrecht focuses on IgM-associated polyneuropathy. He is one of the principal investigator of the IMAGiNe study, a collaboration between the UMC Utrecht and Maastricht UMC+ and currently the world’s largest prospective cohort of patients with this condition. His work includes clinimetric studies on outcome measures, longitudinal clinical analyses, and biomarker research aimed at improving disease monitoring and trial readiness. In addition to his research activities, he works as a neurologist at Tergooi MC.

Research: IMAGiNe (IgM ± anti-myelin-associated-glycoprotein [MAG] peripheral neuropathy) study

Expertises: IgM associated polyneuropathy, immune-mediated polyneuropathy, big data analysis